• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line).
  

PubMed=26735014; DOI=10.1038/nature16508
Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P., Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E., Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C., Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K., Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E., Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S., Meyer C.A., Bradner J.E., Polyak K.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature 529:413-417(2016)

PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027
Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B., Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K., Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S., Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W., McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B., Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S., Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F., Polyak K.
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer.
Mol. Cell 78:1096-1113.e8(2020)